Clinical Trial

Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This phase I trial studies the side effects and best dose of cellular immunotherapy in treating patients with high-risk acute lymphoblastic leukemia. Placing a modified gene into white blood cells may help the body build an immune response to kill cancer cells.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-07-15 -> 2027-06-17 2026-08-06
minor Completion pushed: 2026-07-15 -> 2027-06-17 2026-08-06
Trial Details
NCT Number NCT02146924
Lead Sponsor City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Conditions B Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Enrollment 71 participants
Start Date 2014-10-16
Primary Completion 2027-06-17 (estimated)
Study Completion 2027-06-17 (estimated)
Updated on ClinicalTrials.gov 2026-08-05